slamming on the rnai brakes

The latest Novartis action to shutdown RNAi research based on:

"... the lingering problems associated with delivering these therapies tied to the small number of relevant targets they could shoot for drove the move."

http://www.fiercebiotech.com/story/breaking-novartis-slams-brakes-rnai-development-efforts/2014-04-14

This contrasts with the EET and potential Phenomica progress in which:

- The delivery problem has been completely resolved;

- The targeting problem looks like it can be feasibly addressed; and

- The complex RNA payload against gene expression can be replaced with a simple payload against phenotype expression.

Compare the multiple billion$ directed to RNAi programmes - where Phylogica's tens of million$ actually has produced a significantly more effective platform.